The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
As long as you can be patient you will be rewarded. Completely under the radar.
Outlook upgrade and 2.8m cash with a market cap of 9.8m this is priced at just over 1x revenue projected at 6.2m this year. Inflection point is reached but as always this company is not sexy enough for most AIM dreamers...
This will wake up once more. The share consolidation has done nothing for the spread at this point given the volumes are nonexistent but news will help. With a 84% gross margin this is a great business and given we have reached peak capex this year on software and headcount I hope to see the cost of sales to start to fall rapidly from here. The ARR rate of 5.8m this year supports the 20% growth projections but I guess the market was just spooked by the loss of one client to insolvency and a higher churn rate of 5% which, I assume comes from the beepro element which they have wisely sidelined.
ABITDA profitability is a nonsense for me but we should be heading for real profit next year and strong cash flow. The opportunity of the US market is not priced in at all either so all to play for..
Added another 500k shares..biggest holding now
And in come the bargain hunters...pays to do nothing more often than not with shares like this ...
Gotta laugh at people dumping this at these prices. Almost to 'dash for cash' 2020 levels .... bizzare for a company with no debt and a growing market...hey ho
The lesson I learnt with this chairman and his CEO was with Wey Education where he successfully de-vested the over reach of global ambitions of the previous board and slowly turned the business around. I was critical of him at the time and told him so but he proved me wrong and took the business to another level before selling it at a premium.
The same is happening here but this business has always been his main interest. The gross margins are impressive and his careful use of capital to grow organically is not to everyone's taste but the board are a class act and even the reduction in growth projections for H2 are matters beyond their control . In short I've bought more and I learnt to trust the directors here..IMO of course.
Well someones keen to offload ....can't fathom why nut hey that's AIM for ya !
On the cusp of profitability and real scale and yet, ignored. Good ....
Well worth a read on the AR to understand what they do.
https://crimsontide.co.uk/wp-content/uploads/2023/05/Annual-Reports-and-Accounts-2022.pdf
Hopefully it is a hidden gem. Growing at 25-30% per year. P/E of 10 for next years. High margin, low churn rate. Cash of £3m.
Management own a lot, relatively low salaries and have sold businesses before.
on board, William Currie Investments. Also Bill Currie taken a slice himself
.
Worth a look at the website.
Interims were good, too.
Nice rns. It's on the move now. Not many following this. I was not until I read this mornings rns.
Looking at the notes in the RNS we have the ex CEO concentrating on growth and a new CEO who managed her last company through to a sale. All good
I think the latest rns is very positive. The new roles are encouraging and perhaps now Mypro will start to be in demand. This needs to start growing to keep small Pi's interested. It has not to date.
A nice contact win trumping last weeks news. 12% on revenue between them. A few more of those and we can look forward to a buy out.
DYOR GLA BlaBla
Wonder if they will pist any positives.. Zzzz
I've been waiting since about 2013, not sure what's changed here. Always seems jam tomorrow with this share.
Classic MM manoeuvring...
Price collapse followed a few days later by a press release for a new large contract!
Still a bargain though at 2.7p if you can wait until late 2022 or 2023.
JOLLYSPECULATOR
Thanks, I missed Whipp selling 10% and another director selling 5%. Offset I suppose by three directors participating in the Placing to a somewhat limited extend. Not sure what conclusions can be drawn from the transactions as Whipp still has a huge shareholding.
look at sales within last placing
Jollyspeculator
I see no recording of director sales at 3.0p. Large NED purchase @2.99p on 11 Oct 2021. Purchases were previously made on 23 April 2021 by various Directors. Please clarify.
extraordinarily poor communications....where had they mapped out huge swing to losses!!
confirms big director selling @3p as red flag
#lifestyleshare
tp <2p
Does anyone understand the trading update? For example what is meant by 'the deployment of investment capital led to slightly smaller losses for the year than the £700k expected at the EBIT and PBT levels.' Since this company has made increasing +ve PBT over the last three years and showed a PBT of £0.257K at the half way stage. Also under 'OUTLOOK' the RNS states '....our goal remains to reach EBITDA break even during 2022'. Yet they have been more than breaking even at EBITDA level for the past few years. F we take these statements at face value the implications are a large loss during the second half of the year or am I missing something. Anyone like to enlighten me.